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1. Introduction 
Parkinson’s disease (PD) is a relentlessly progressive disorder causing disability in most 
individuals and cannot be controlled with available medication. PD is currently considered 
a systemic disease with complex motor disorders and non-motor deficits which appear 
before or in parallel with motor deficits and then worsen with disease progression 
(Chaudhuri et al., 2006; Ferrer et al., 2010). In a recent survey, the projected number of 
individuals with PD will dramatically increase in 20 years especially in the most populated 
countries like China, India, Brazil and the United States (Dorsey et al., 2007). Current 
causative theories for PD include complex interactions between genetic susceptibility and 
environmental factors. These and possibly other mechanisms lead to a progressive and 
variable degree of dopamine (DA) neuron loss in the substantia nigra compacta (SNc) 
resulting in DA depletion in the striatum (Hornykiewicz & Kish, 1987; Marsden & Obeso, 
1994) that then leads to the clinical manifestation of PD. Studies have demonstrated that PD 
is characterized by a presymptomatic phase, likely lasting years, or even decades, during 
which neuronal degeneration is occurring but before clinical symptoms appear (Hubble, 
2000; DeKosky & Marek, 2003; Katzenschlager & Lees, 2004). In addition, studies have 
demonstrated that most patients when diagnosed with PD have already lost a significant 
amount of SNc DA neurons in the range of 50% cell loss. Based on detailed pathological 
studies, Fearnley and Lees (1991) have proposed the notion that the loss of nigral neurons 
would occur exponentially, with greater loss occurring within the first decade in the disease 
process, and then reaching over 90% loss at the time of death.  
While our understanding of PD has grown over the course of the last two centuries and PD 
is one of the best understood neurodegenerative diseases, our ability to treat PD remains 
limited. Given the progressive nature of the disease, the question becomes is it possible to 
divert or change the rate of the progression? Inherent to this question is our ability to 
identify where an individual is along the path of this disease. Thus it would behoove us to 
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be able to establish indicators of the disease stage while intervention remains a possibility. 
Here we describe the development of using non-invasive functional imaging as a biomarker 
for the early diagnosis of PD. 
1.1 Difficulty of early detection of PD 
The diagnosis and treatment of PD is fraught with problems: 1) so far, no objective measures 
are available for the diagnosis of PD (Wu et al., 2011); 2) it is unknown whether a linear 
relationship exists between a worsening in the Unified Parkinson’s Disease Rating Scale 
(UPDRS), or other clinical scales, and the progressive degeneration of the nigrostriatal 
system; 3) no objective measures are available for testing responsiveness of therapy. 
Therefore, biomarkers of disease progression before the appearance of symptoms would be 
of onsiderable value; thus, neuroimaging techniques may be good candidates for meeting 
the challenges. In the past decade, radiotracer imaging of the nigrostriatal dopaminergic 
system has been extensively explored with positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) imaging protocols and has become a 
prominent biomarker in PD although these techniques are still controversial in some aspects 
such as the interpretation of imaging data and disconnection with clinical outcomes (Brooks 
et al., 2003; Ravina et al., 2005). However, the spatial resolution of these techniques is 
relatively poor, thus reducing their utility in mapping subtle changes in neuroanatomy and 
neurochemistry with PD progression (Snow et al., 2000). Furthermore, PET imaging is not 
widely available and is expensive (~US$3,000-$6,000) because of the need to generate and 
use radioactive nucleotides onsite. Clearly there is a need for imaging techniques that do not 
require radioactive isotopes but ones that would still be sensitive enough to usefully and 
longitudinally monitor the development, progression, and treatment of PD. The ideal 
technique would 1) permit high-resolution imaging of brain sites affected by PD processes, 
2) provide valid assessment of the underlying neuroanatomical state, and 3) be safe to allow 
repeated tests. A hypothesis for PD is that the disease severity corresponds to the magnitude 
and pattern of histological and neuroimaging abnormalities (DeKosky & Marek, 2003; 
Eckert & Eidelberg, 2004; Seibyl et al., 2005). Based on our own previous studies, and those 
of others in rodents, nonhuman primates, and humans, pharmacological MRI (phMRI; or 
functional MRI with specific pharmacological stimulation) would be a good candidate 
because of its high resolution, sensitivity, reproducibility, wide availability, and low cost 
(Nguyen et al., 2000; Tracey, 2001; Honey & Bullmore, 2004; Jenkins et al., 2004; Chin et al., 
2008; Thiel, 2009; Rasmussen Jr, 2010).  
1.2 Why is a new imaging protocol needed for PD? 
In the past decade, PET and SPECT have become the most widely used and accepted 
imaging methods for PD research (de la Fuente-Fernandez & Stoessl, 2002; Eckert & 
Eidelberg, 2004). Worsening motor disability along with 18F-dopa uptake decreases in the 
putamen (Brooks et al., 1990) correlate with the storage of DA within vesicles (Hoshi et al., 
1993) and with the number of functioning DA terminals in the striatum (Snow et al., 1993). 
Currently, in vivo measurements can be conducted using SPECT with ligands for the DA 
transporter (DAT) such as [(123)I]N-omega-fluoropropyl-2beta-carbomethoxy-3beta-{4-
iodophenyl}nortropane (FP-CIT) that provide a measure of DA terminal integrity (DeKosky 
& Marek, 2003; Andringa et al., 2005). Although the aforementioned studies have shown that 
these neuroimaging techniques are capable of mapping changes in dopaminergic function in 
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the basal ganglia, much controversy still exists. Recent problems have been encountered in 
clinical trials that have used radioligand imaging to quantify medication response. For 
example, there appears to be a discrepancy between current imaging protocols and clinical 
outcomes. In National Institutes of Health (NIH) sponsored randomized double-blind 
studies on PD patients receiving either fetal tissue transplants or sham surgery, a 40% 
increase in 18F-dopa uptake in the putamen contrasted with a modest (non-significant) 18% 
improvement in the mean UPDRS in one study involving 40 patients (Freed et al., 2001). In 
the second study involving 34 patients, a 20-30% increase of 18F-dopa uptake was seen in the 
striatum, but clinical changes failed to reach statistical significance (Brooks, 2004). Most 
recently, a significant increase was found in 18F-dopa uptake in the putamen of PD patients 
receiving trophic therapy, while clinical improvements did not differ significantly from the 
control group (Lang et al., 2006).  
1.3 What are imaging biomarkers for PD? 
In general, biomarkers must be biologically and clinically relevant, analytically sound, 
operationally practical, timely, interpretable and cost effective. On the other hand, 
biomarkers must be objectively measured indicators of biological and pathobiological 
process or pharmacologic responses to treatment. The biomarkers should be used to 
substitute for a clinical endpoint (predict benefit or harm) based on epidemiologic, 
therapeutic, pathophysiologic or other scientific evidence (Biomarkers definition working 
group, 2001). Specifically for PD, the biomarkers must be indicators of biological processes 
that change with the progression of the nigrostriatal system. The biomarkers should 1) 
correlate to some extents with severity of PD assessed by behavior and with 
pathophysiological changes such as the number of surviving neurons in the SNc; 2) reflect 
true disease status or predict clinical outcomes; 3) be used to assess efficacy and/or 
responsiveness of treatment, and 4) be used as surrogate endpoints. 
1.4 What is BOLD-phMRI?  
Our preliminary studies have shown evidence that blood-oxygenation-level-dependent 
(BOLD)-phMRI can be used as a non-invasive imaging modality to detect functional 
changes of the dopamine system in parkinsonian monkeys. More importantly, the studies 
were conducted in a conventional clinical MRI scanner without the injection of contrast 
agents. Using this imaging method, a significant correlation was found between the 
amphetamine-evoked BOLD response and the number of surviving dopamine neurons in 
the substantia nigra, which was also significantly correlated with bradykinesia scores on the 
nonhuman primate parkinsonian rating scale (Ovadia et al., 1995), suggesting that phMRI 
may be used as a biomarker to assess dopamine neuronal loss in PD. Recently, fMRI has 
become a popular tool for imaging of functionally active brain regions in healthy and 
diseased brains. The use of fMRI is promoting the emergence of a new area of research, one 
that is complementary to more invasive techniques for measuring neural activity in animal 
models while better understanding the function and dysfunction of the human brain. The 
most common method of fMRI is the BOLD imaging technique. fMRI takes advantage of the 
coupling between neural activity and hemodynamics (the local control of blood flow and 
oxygenation) in the brain to allow the non-invasive localization and measurement of brain 
activity (Fig. 1).  
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Fig. 1. fMRI provides an insight into neural activity. The BOLD signal has several 
constituents: (1) the neuronal response to a stimulus or background modulation; (2) the 
complex relationship between neuronal activity and triggering a haemodynamic response 
(termed neurovascular coupling); (3) the haemodynamic response itself; and (4) the 
detection of the response by an MRI scanner (from Arthurs & Boniface, 2002). 
 
 
 
Fig. 2. Using phMRI for the early diagnosis of PD. As part of a multi-factor approach, 
phMRI provides a possible means of screening for the underlying neurological changes in 
parkinsonism or PD. 
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We hypothesize that the BOLD-fMRI response to a specific DA stimulation could serve as a 
potential biomarker for PD because of its unique features which are different from other 
neuroimaging technologies as follows: 1) High sensitivity and reproducibility, and relatively 
high specificity, 2) Minimal invasiveness or patient discomfort ("subject friendly"), 3) Low 
per-usage cost (this is especially important if widespread screening is contemplated), and 4) 
wide availability. 
2. phMRI detects dopamine deficiency in parkinsonian monkeys 
2.1 An animal model of dopamine deficiency in rhesus monkeys 
A reliable and reproducible model of dopamine deficiency/a model simulating human PD 
is developed by unilateral administration of neurotoxin 1-methyl-4-phenyl-1,2,3,6-
etrahydropyridine (MPTP) through the carotid artery. The specific neurotoxic actions of 
MPTP are produced when it is metabolized by monoamine oxidase B into 1-methyl-4-
phenylpyridinium (MPP +), a complex I mitochondrial neurotoxin with relative specificity 
for dopamine neurons in the substantia nigra (Langston & Ballard, 1983; Nicklas et al., 1987; 
Richardson et al., 2007). Ding and colleagues (2008) described the key features modeled by 
MPTP toxicity including 1) all animals show parkinsonian features often seen in idiopathic 
PD such as bradykinesia, rigidity, postural, and balance instability, 2) these PD features can 
be partially normalized by levodopa treatment, which is the most efficacious drug to treat 
PD motor symptoms and is widely considered the “gold standard” treatment for the 
disease, 3) massive neuronal loss of dopaminergic neurons in the SNc and dopaminergic 
fibers in the striatum, and 4) remarkable declines in DA and DA metabolites.  
2.2 phMRI procedures 
1) Mapping of MPTP-induced functional changes with d-amphetamine stimulations (from a 
pre-synaptic perspective) and 2) Mapping of MPTP-induced functional changes with APO 
challenge (from a post-synaptic perspective). In early studies, the scans were conducted on a 
Siemens VISION 1.5 T MRI scanner using the body coil to transmit radio frequency and an 8 
cm diameter surface coil placed above the monkey’s head for RF signal reception. The 
anatomical structures of interest were visualized using a 3D FLASH sequence with 1 mm 
isotropic resolution (TR/TE=21/6 ms, flip angle = 30°, image matrix size = 128x128x90, field 
of view = 128 mm). The functional MR images from pharmacological challenges were 
acquired continuously using a FLASH 2D multiple gradient-recalled-echo (MGRE) 
navigator sequence (Chen et al., 1996). The ROI dimensions were 3x3x3 mm, each 
representing a 27 mm3 volume. ROIs were manually selected in both hemispheres of MPTP-
lesioned and normal control animals based on the co-registered 3D anatomical images 
acquired from the FLASH sequence. Because of variability in the inherent noise level due to 
differences in positioning animals for each scan and the movements during scanning, the 
replicate scans were treated as independent observations in the analysis. For later studies, 
images were acquired on a Siemens 3T Trio clinical MRI system using a dedicated receive-
only coil for reception, which was designed and developed by our group. The BOLD-effect 
weighted MR images used to measure the phMRI response were acquired in an 
anatomically coronal plane. The image planes of the acquisition were arranged to cover the 
motor cortex and the basal ganglia. A segmented gradient-echo EPI sequence with TE=28 
ms and a turbo factor of 7 was used to reduce echo train length and minimize magnetic 
susceptibility-related artifacts. The EPI sequence acquisition parameters are FOV=112x98 
mm and image matrix 64x56 for an in-plane resolution of 1.75 mm. A total of 15 contiguous 
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slices, each 2 mm-thick, were acquired at a rate of 15 s per EPI volume. The overall scan 
duration was 80 minutes with 128 volumes acquired prior to apomorphine (APO) 
administration as a baseline and 192 after APO to track the response. Images were motion 
corrected and spatially smoothed using a Gaussian kernel of width 3.5 mm. phMRI response 
was calculated as the fractional signal change in % of the average of the post-APO image 
data relative to the pre-APO baseline. A co-registered high-resolution (0.67×0.67×1 mm) T1-
weighted anatomical MRI scan was acquired in each session for spatial localization of the 
activation response. Prior to the administration of d-amphetamine (2.0mg/kg) or APO (0.1 
mg/kg), a total of 40 image frames were collected over 20 min to determine the baseline 
state. Following injection of d-amphetamine or APO, an additional 40 frames were collected 
to track the dynamic response (Zhang et al., 2001; Andersen et al., 2002). The change in R2*, 
i.e. R2* which represents the phMRI activation response to drug, was determined as the 
difference between the mean R2* across 20 images post drug administration during the 
period of peak response (5-15 min) and the mean R2* within the 40 baseline images. A 
reduction (“negative” change) in R2* associated with a local decrease of paramagnetic 
deoxyhemoglobin is an indicator of BOLD-effect activation (Chen et al., 1996).  
2.3 phMRI-responses correlate with severity of PD 
Six out of six animals responded positively to APO treatment represented by 44% 
improvements in parkinsonian symptoms. The same dose of APO also evoked phMRI 
responses by increasing the phMRI signal intensity. The typical phMRI (BOLD effect) 
responses to APO were gradually increased after APO administration only in the structure on 
the ipsilateral side receiving MPTP administration. Interestingly, but not surprising, APO-
induced behavioral changes (PD features) were significantly correlated with APO-induced 
phMRI responses in the putamen, premotor cortex, and cingulate gyrus. When compared with 
standard but objective measures, there was a significant negative correlation between the 
phMRI responses in the putamen and distance travelled and movement speed. Similar 
relationships were also seen between phMRI responses in the motor cortex and daytime home-
cage activity and between phMRI responses in the caudate nucleus and movement speed.  
 
 
Fig. 3. phMRI reveals nigrostriatal system responsiveness to dopamine stimulation. Coronal 
MRI scans depicting areas of activation and deactivation (represented by the psedudocolor) 
in the brain after an APO or amphetamine challenge in unitalteral MPTP-lesioned 
nonhuman primates (from Zhang et al., 2006). 
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2.4 phMRI-response and MPTP-induced dopamine deficiency 
2.4.1 phMRI responses in MPTP-lesioned structures 
Apomorphine administration strongly activated the MPTP-denervated putamen (Figs. 3A 
and 4C) and substantia nigra (Fig.4D). An opposite response (a positive ΔR2* value) was 
evident in the contralateral putamen (Fig. 4G) and substantia nigra (Fig. 4H). The differences 
between the intact and lesioned substantia nigra and between the intact and lesioned 
putamen were highly significant, P < 0.01(t-test), in both cases. In contrast, ΔR2* responses in 
the caudate nucleus and in the corpus callosum were not significant, nor were there 
significant hemispheric differences in activation or deactivation with the contralateral 
caudate or with a comparable region in the contralateral callosum (Figs. 4A and 4E).  
The phMRI responses to amphetamine treatment in the putamen (Figs. 3B and 4G) and 
substantia nigra (Fig. 4H) were the inverse of those seen with apomorphine. Amphetamine-
induced decreases (positive ΔR2* values) in the lesioned putamen and substantia nigra 
suggested diminished neuronal activity in both sites. In contrast, amphetamine induced the 
opposite ΔR2* response in the intact left side, tending to increase activation in the putamen 
and substantia nigra. The responses in the intact putamen and intact substantia nigra were 
significantly different from their lesioned counterparts. Again, the corpus callosum and the 
caudate nucleus displayed only small, insignificant changes in response to amphetamine 
stimulation (Figs. 4E and 4F). 
 
 
Fig. 4. phMRI responses in the nigrostriatal system. Depending on the means of stimulation, 
phMRI reveals a differential activations and deactivations in the nigrostriatal system. After 
APO stimulation (A-D) or d-amphetamine stimulation (E-H). **P<0.01; *P<0.05; unpaired t-
test (from Zhang et al., 2006). 
2.4.2 phMRI-responses and loss of DA neurons in the SN 
In a later study, post-mortem histopathological evaluation revealed that the unilateral MPTP 
administration (received 5 years before the analysis) produced a massive (85%) loss of the 
rate-limiting enzyme for DA formation, tyrosine hydroxylase, (TH+) cells in the midbrain on 
the ipsilateral side receiving the infusion of the neurotoxin. TH+ cell numbers were 
significantly higher on the un-lesioned side compared to the MPTP-lesioned side. More 
importantly, the number of TH+ cells was strongly correlated with the phMRI responses in 
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the caudate nucleus and in the cingulate gyrus. When comparing d-amphetamine-induced 
DA release in the putamen and DA neuron counts in the SNc, a significant correlation was 
also seen. In an earlier study (Zhang et al., 2006), amphetamine administration evoked a 
BOLD response in the SN that correlated with the number of TH+ dopamine neurons in the 
same structure. These data support that there is a strong relationship between BOLD-
responses to dopaminergic challenge and the number of dopaminergic neurons in the 
midbrain. 
2.4.3 phMRI-responses and loss of DA fibers in the striatum 
Similar to the effect on dopaminergic neurons, the MPTP administration also produced a 
remarkable reduction of TH+ fibers on the ipsilateral side of the lesion. A comparison of the 
fiber density in the putamen on the MPTP-lesioned side with other elements of the cortico-
basal ganglia-cortical circuit (Braak & Del Tredici, 2008) such as ipsilateral phMRI responses 
in the motor cortex (Fig. 5A) and caudate nucleus (Fig. 5B) showed strong correlations. In 
addition, the fiber density in the MPTP-lesioned caudate nucleus was strongly correlated 
with phMRI responses in the premotor cortex, caudate nucleus, and cingulate gyrus. Those 
changes in TH+ fiber density were also correlated with behavior and DA levels in the 
striatum and with the number of DA neurons in the SNc.  
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Fig. 5. Lower TH+ fiber density in the ipsilesional putamen corresponds with higher phMRI 
activation. TH+ fiber density in the right putamen (R-Put) is inversely correlated with 
phMRI activation in A) the right motor cortex (R-MC) and B) the right caudate nucleus (R-
CD). 
2.4.4 phMRI-responses correlate with dopamine overflow 
The microdialysis experiments were conducted months after the parkinsonian symptoms 
had been fully developed and stabilized. First, the single administration of MPTP produced 
significant reduction in both potassium- and d-amphetamine-evoked overflow of DA in the 
putamen (Fig. 6A) and SNc (Fig.6B) on the ipsilateral side of the lesion. Second, there were 
several important correlations between DA levels in the putamen and SNc and the phMRI 
responses. For example, both potassium- and d-amphetamine-evoked overflow of DA in 
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Fig. 6. Hemiparkinsonian nonhuman primates have markedly dimished dopaminergic 
function. K+ (100 mM)- and amphetamine (250 µM)-evoked DA release was significantly 
attenuated in the ipsilesional A) putamen (Put) and B) SNc; ***: P < 0.0001 (paired t-test). 
the putamen (each measured for a single time point, 30 minutes after stimulus 
administration) had significant correlations with phMRI responses in the putamen. DA 
levels in the putamen were also significantly correlated with phMRI responses in the 
premotor cortex and cingulate gyrus, as well as in the caudate nucleus. Finally, d-
amphetamine-evoked DA release in the SNc was found to have a significant, but negatively 
correlated relationship with the motor cortex (Fig. 7).  
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Fig. 7. DA levels in the right SNc correlate with the BOLD responses in the right motor 
cortex. In animals with lower DA levels in the right SNc, less activation was observed in the 
right motor cortex 
3. Using phMRI to monitor therapeutic effects in parkinsonian monkeys 
There is a great need for the development of noninvasive, highly sensitive, and widely 
available imaging methods which can potentially be used to longitudinally monitor 
treatment of PD. We reported the monitoring of glial-cell-line-derived neurotrophic factor 
(GDNF) induced functional changes of the basal ganglia in hemiparkinsonian monkeys via 
phMRI measuring the BOLD response to a direct dopamine agonist, APO, (Luan et al., 2008). 
The effectiveness of GDNF to protect and restore the nigrostriatal dopaminergic system in 
rodent and nonhuman primate models of PD has been extensively documented (Beck et al., 
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1995; Tomac et al., 1995; Gash et al., 1996; Kordower et al., 2000; Grondin et al., 2002). This 
trophic factor has also shown promise in Phase I clinical trials for the treatment of PD (Gill et 
al., 2003; Slevin et al., 2005). Ample evidence supports the idea that GDNF can protect and 
promote survival of pre-synaptic dopaminergic neurons in the SNc and axons in the 
striatum (Gash et al., 1996). After testing BOLD responses to APO in their normal state, 
additional scans were taken with the same dose of APO stimulation after MPTP-induced 
hemiparkinsonism. Then, the animals were chronically treated with GDNF for 18 weeks by 
a programmable pump and catheter system. The catheter was surgically implanted into the 
right putamen and connected to the pump via flexible polyurethane tubing. phMRI scans 
were taken at both 6 and 18 weeks while they received 22.5µg of GDNF per day (Fig. 8). In 
addition, behavioral changes were monitored throughout the entire study. The primary 
finding of this study was that APO-evoked activations in the DA denervated putamen were 
attenuated by the chronic intraputamenal infusion of GDNF accompanied by improvements 
of parkinsonian features, movement speed and APO-induced rotation compared to data 
collected before the chronic GDNF treatment. The results suggest that phMRI methods in 
combination with administration of a selective DA agonist may be useful for monitoring 
neurorestorative therapies in PD patients in the future.  
 
 
Fig. 8. phMRI (BOLD)-responses to APO can be used to monitor GDNF-induced 
neurorestorative therapeutic effects in rhesus monkeys with MPTP-induced 
hemiparkinsonisms. phMRI activation reveals differences in dopaminergic activity after 
GDNF treatment (from Luan et al., 2008). 
4. Brain iron and motor deficits in rhesus monkeys 
Schuff (2009) notes in a recent review, perhaps the most consistently reported MRI findings 
in PD have been the detection of signal changes related to excessive iron, most likely related 
to ferritin, the main iron-storage protein within the brain. Under normal condition, iron is 
essential for normal metabolism and used in production of DA. Brain iron may also play an 
essential role in learning and memory (Fretham et al., 2011). Several years ago, we reported a 
correlation of R2 with total iron concentration in the brains of rhesus monkeys (Hardy et al., 
2005). The results show that the transverse relaxation rate R2 = 1/T2 is highly correlated to 
and varies linearly with iron content. In the study, Hardy and colleagues demonstrated that 
R2 was highly correlated with the total iron concentration and that the relationship between 
R2 and tissue iron concentration appeared to depend upon the iron concentration. In another 
multidiscipline study of brain iron in a large group of rhesus monkeys ranging in age from 4 
A. Pre-GDNF B. Post-GDNF
www.intechopen.com
 
Developing an MRI-Based Biomarker for Early Diagnosis of Parkinson's Disease 
 
125 
to 32 years old, Cass and colleagues (2006) found significant decreases in motor 
performance, decreases in striatal DA release, and increases in striatal iron levels in rhesus 
monkeys as they aged from young adulthood. A comprehensive statistical analysis relating 
age, motor performance, DA release, and iron content indicated that the best predictor of 
decreases in motor ability, above and beyond levels of performance that could be explained 
by age alone, was iron accumulation in the striatum.  Compared to the young animals, the 
relaxation rate 1/T2* used as an indicator of iron content was elevated by 38-43% in all three 
regions in the middle-aged monkeys (Fig. 9). In the aged animals, iron content was 
increased by 55%, 61%, and 79% in the caudate, putamen, and nigra, respectively, compared 
to the young animals (Fig. 9). Iron content in the nigra of the aged animals was also 30% 
higher than in the middle-aged animals. ROI data for 1/T2 measures are not shown but 
exhibited a similar dependence on age. Regression analysis extended the group statistics 
and further confirmed the strong age-associated increase of the MRI relaxation rate 1/T2* 
(equivalent to a T2*-shortening) in each of the three regions of interest (n = 24; p<0.0001). The 
intercept and rate of increase were 16.537+ 0.598 sec-1/year, 15.728+0.734 sec-1/year, and 
19.047+0.791 sec-1/year for the caudate, putamen, and substantia nigra, respectively. This 
suggests that striatal iron levels may be a biomarker of motor dysfunction in aging; and as 
such, can be monitored non-invasively by longitudinal brain MRI scans.  
 
 
Fig. 9. Using MR imaging of iron content to identify alterations in the aging brain. The use of 
MR imaging to identify the relative iron content in particular brain structures illustrates the 
potential usefulness for a non-invasive means of assessing changes in the nigrostriatal 
system with aging. *: P <0.05; #: P <0.01 (one-way ANOVA). (from Cass et al., 2006) 
5. Diffusion Tensor Image (DTI) and dopamine deficiency in rhesus monkeys 
Diffusion tensor imaging (DTI) has been increasingly used in PD related research (Schuff, 
2009). DTI can be used to noninvasively investigate and identify white matter (WM) changes 
associated with PD. DTI is able to obtain quantitative information about fractional anisotropy 
(FA) and mean diffusivity (MD). A diminished FA is thought to reflect axonal loss and 
demyelination. A recent DTI study was conducted by our group in normal (n=9) and 
hemiparkinsonian (n=8) monkeys to explore the MPTP-effects on WM using the DTI 
parameters of FA and MD. Under general anesthesia, DTI data was obtained on a 3T Siemens 
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Trio MRI scanner with a custom-built, single channel, receive-only coil, built on a fiberglass 
frame and used to enhance the received signal. Imaging consisted of single shot (SS), double 
pulsed gradient spin echo (double-PGSE), diffusion weighted, echo planar imaging (EPI) with 
a spatial resolution of 1.23×1.23×2.0 mm3. Images were processed and analyzed by using the 
publicly available image processing software FSL (http://www.fmrib.ox.ac.uk/fsl) (Smith et 
al., 2004; Smith et al., 2006). All of the processing tools referred to by their FSL acronyms are 
available for download at the website. First, we observed a WM tract in the vicinity of the 
basal ganglia (BG) with FA greater (P<0.01, t-test) in the aged-matched control animals than 
MPTP-treated animals in the same structure. Second, we observed multiple WM tracts in the 
sensory cortex, with FA greater (P<0.05, t-test) in the MPTP-treated than untreated side in the 
same animals. The result from the pilot study supports the idea that high resolution DTI has 
the potential to distinguish animals with a MPTP-lesioned nigrostriatal system from normal 
age-matched, healthy controls on an animal-by-animal basis. 
6. Conclusion and perspectives 
Since a diagnosis of PD still solely depends on the judgment of the clinician, there is an 
urgent demand for the development of reliable and applicable test systems or biomarkers to 
provide a level of certainty to the diagnosis. Objective biomarkers of PD are pivotal to 
tracking the disease progression and confirm the therapeutic effects. Non- or minimally-
invasive imaging techniques provide a unique, real-time opportunity to assess the changes 
that occur with neurodegenerative diseases. In addition, with the rapidly expanding use of 
fMRI to provide a dramatically greater understanding of brain function, imaging techniques 
such as phMRI are only bound to benefit from this new wealth of knowledge. 
The advantage of MRI is that MRIs are far more widely available than other imaging 
modalities and are most commonly used in clinical practice to differentiate idiopathic PD 
from secondary cause of parkinsonism (Pavese & Brooks, 2009). Recent advancement in 
high field MRI technology offers even better opportunities for noninvasively, longitudinally, 
and objectively assessing brain alterations in PD. For example functional and 
pharmacological MRI has been increasingly employed for preclinical and clinical research of 
the disease. Ample evidence supports that MRI signals have the potential to be developed as 
a noninvasive state biomarker in PD. For example, several MRI methodologies such as 
structural MRI, imaging of brain iron, DTI, functional MRI and pharmacological MRI have 
provided meaningful insight of brain alteration in PD. That said, we note that while we have 
gained greater understanding of the changes that occur in disorders of dopaminergic 
dysfunction with the use of phMRI in the rhesus model of PD, nevertheless the studies are 
works in progress and ones that still require cautious interpretation because conditions in 
patients with PD are more complex than in the animal model used in these studies. 
In our hands, MRI studies conducted at the University of Kentucky have demonstrated that 
phMRI-responses to dopaminergic challenges in MPTP-treated monkeys are highly 
correlated with 1) the severity of parkinsonism, 2) the loss of dopamine neurons and 
terminals, 3) the decline of dopamine overflow and 4) the functional recovery from GDNF 
treatment. In addition, results from imaging brain iron suggest that striatal iron levels may 
constitute a biomarker for motor dysfunction in aged animals with parkinsonism. As shown 
in Fig. 10, combining various MRI methodologies may be used to screen populations at high 
risk, to differentiate idiopathic PD from second causes of parkinsonisms, and to monitor 
progression of the disease and the therapeutic effects.  
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Fig. 10. Employing MRI methodologies in the clinic for PD. 
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